dr. hou on polatuzumab vedotin in dlbcl
Published 5 years ago • 469 plays • Length 2:07Download video MP4
Download video MP3
Similar videos
-
1:35
dr. pagel on the implications of polatuzumab vedotin approval in dlbcl
-
2:22
dr. herrera discusses polatuzumab vedotin in dlbcl
-
43:40
polatuzumab vedotin in previouslyuntreated diffuse large b-cell lymphoma.
-
1:47
dr. hou on the latest updates with car t-cell therapy in dlbcl
-
1:52
dr. diefenbach on polatuzumab vedotin plus obinutuzumab and lenalidomide in fl
-
4:59
a breakthrough therapy: polatuzumab vedotin plus br for r/r dlbcl
-
4:25
phase ib polatuzumab vedotin trial
-
21:26
polatuzumab fda approval in dlbcl (polarix) & swog s1826 nivo vs. bv in hodgkin's lymphoma
-
2:19
dr. kahl discusses polatuzumab vedotin in lymphoma
-
2:00
polatuzumab vedotin and car t-cell therapy for diffuse large b-cell lymphoma
-
3:12
polarix: polatuzumab vedotin and r-chp superior to r-chop in dlbcl
-
3:25
how will front-line use of polatuzumab vedotin influence patient outcomes in dlbcl?
-
5:46
glofitamab and polatuzumab vedotin in dlbcl
-
4:39
treatment alternatives to chemotherapy in r/r dlbcl
-
4:31
adc polatuzumab vedotin in combinations for relapsed lymphoma
-
0:58
polatuzumab in diffuse large b-cell lymphoma
-
2:28
improving outcomes for r/r dlbcl with polatuzumab vedotin
-
3:40
does polatuzumab vedotin, venetoclax, and rituximab combined enhance tumor responses in r/r dlbcl?
-
1:15
polatuzumab vedotin combined with chemotherapy in untreated large b-cell lymphoma